Indications
Therapeutic Asset Ratings
91,565
assets
·
7,904
sponsors
·
3,128
indications
Methodology v0.2
Filters
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Amrubicin
Small Cell Lung Carcinoma
AbbVie
P3
BB
(71)
Antihemophilic Factor,Human,Method M,Monoclonal
Hemophilia A
Dhaka Medical College
P3
BB
(71)
Asparaginase
B-Cell Acute Lymphoblastic Leukemia
University of Washington
P3
BB
(71)
Autologous Cd34+ Cells Isolated From Mobilised Peripheral Blood By Positive Selection, Modified By Crispr/Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats/Crispr-Associated Protein 9) Mediated Gene Editing Consisting Of A Guide Rna (Grna) Introduced Transiently As Ribonucleoprotein (Rnp) Complex, Targeting The Erythroid Lineage-Specific Enhancer Region Of Bcl11A (B-Cell Lymphoma/Leukemia 11A). The Site-Specific Cleavage By Cas9 Forms A Double Strand Break (Dsb), Which Is Subsequently Repaired By Nonhomologous End-Joining (Nhej), Leading To The Transcriptional Repression Of Bcl11A, A Repressor Of ?-Globin Gene Transcription
Disease Of Genetic Or Genomic Mechanism
Vertex Pharmaceuticals Incorporated
P3
BB
(71)
Autologous Cd34+ Cells Isolated From Mobilised Peripheral Blood By Positive Selection, Modified By Crispr/Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats/Crispr-Associated Protein 9) Mediated Gene Editing Consisting Of A Guide Rna (Grna) Introduced Transiently As Ribonucleoprotein (Rnp) Complex, Targeting The Erythroid Lineage-Specific Enhancer Region Of Bcl11A (B-Cell Lymphoma/Leukemia 11A). The Site-Specific Cleavage By Cas9 Forms A Double Strand Break (Dsb), Which Is Subsequently Repaired By Nonhomologous End-Joining (Nhej), Leading To The Transcriptional Repression Of Bcl11A, A Repressor Of ?-Globin Gene Transcription
Thalassemia
Vertex Pharmaceuticals Incorporated
P3
BB
(71)
Benzeneethanamine, N-Ethyl-?-Methyl-4-(Trifluoromethyl)-, Hydrochloride, (±)-
Lennox-Gastaut Syndrome
University of Chicago
P3
BB
(71)
Bezisterim
Alzheimer Disease
Neurological Associates of West Los Angeles
P3
BB
(71)
Bortezomib
Lymphoblastic Lymphoma
M.D. Anderson Cancer Center
P3
BB
(71)
Brentuximab Vedotin
Anaplastic Large Cell Lymphoma
Seagen Inc.
P3
BB
(71)
Camizestrant
Breast Cancer
AstraZeneca
P3
BB
(71)
Camustine
Glioblastoma
Leland Metheny
P3
BB
(71)
Camustine
Lymphoma
VIVUS LLC
P3
BB
(71)
Carboplatin
Adenosquamous Lung Carcinoma
NRG Oncology
P3
BB
(71)
Carboplatin
B-Cell Non-Hodgkin Lymphoma
Shanghai Junshi Bioscience Co., Ltd.
P3
BB
(71)
Carboplatin
Bronchial Neoplasm
Nanfang Hospital, Southern Medical University
P3
BB
(71)
Carboplatin
Bronchogenic Carcinoma
Nanfang Hospital, Southern Medical University
P3
BB
(71)
Carboplatin
Chemotherapy-Induced Toxicity
Endeavor Health
P3
BB
(71)
Carboplatin
Fallopian Tube Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
P3
BB
(71)
Carboplatin
Female Reproductive System Neoplasm
Wenjun Cheng
P3
BB
(71)
Carboplatin
Invasive Breast Carcinoma
Baylor Breast Care Center
P3
BB
(71)
Carboplatin
Metastatic Prostate Carcinoma
Case Comprehensive Cancer Center
P3
BB
(71)
Carboplatin
Ovarian Disorder
Fujian Cancer Hospital
P3
BB
(71)
Carboplatin
Respiratory Tract Neoplasm
Fundación GECP
P3
BB
(71)
Chlorambucil
MALT Lymphoma
International Extranodal Lymphoma Study Group (IELSG)
P3
BB
(71)
Cis-Diamminedichloroplatinum Ii
Non-Small Cell Squamous Lung Carcinoma
Gruppo Oncologico Italiano di Ricerca Clinica
P3
BB
(71)
Showing 2326 to 2350 of 42,286 assets
Previous
Page 94 of 1692
Next